Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: Results of a randomized controlled trial

被引:132
|
作者
Hawken, MP
Meme, HK
Elliott, LC
Chakaya, JM
Morris, JS
Githui, WA
Juma, ES
Odhiambo, JA
Thiongo, LN
Kimari, JN
Ngugi, EN
Bwayo, JJ
Gilks, CF
Plummer, FA
Porter, JDH
Nunn, PP
McAdam, PWJ
机构
[1] UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND
[2] KENYA GOVT MED RES CTR,CLIN RES CTR,NAIROBI,KENYA
[3] UNIV NAIROBI,DEPT MICROBIOL,NAIROBI,KENYA
[4] UNIV NAIROBI,DEPT COMMUNITY HLTH,NAIROBI,KENYA
基金
英国惠康基金;
关键词
tuberculosis; isoniazid preventive therapy; isoniazid chemoprophylaxis; HIV-1; AIDS;
D O I
10.1097/00002030-199707000-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To determine the efficacy of isoniazid 300 mg daily for 6 months in the prevention of tuberculosis in HIV-1-infected adults and to determine whether tuberculosis preventive therapy prolongs survival in HIV-1-infected adults. Design and setting: Randomized, double-blind, placebo-controlled trial in Nairobi, Kenya. Subjects: Six hundred and eighty-four HIV-1-infected adults. Main outcome measures: Development of tuberculosis and death. Results: Three hundred and forty-two subjects received isoniazid and 342 received placebo. The median CD4 lymphocyte counts at enrolment were 322 and 346 x 10(6)/l in the isoniazid and placebo groups, respectively. The overall median follow-up from enrolment was 1.83 years (range, 0-3.4 years). The incidence of tuberculosis in the isoniazid group was 4.29 per 100 person-years (PY) of observation [95% confidence interval (CI) 2.78-6.33] and 3.86 per 100 PY of observation (95% CI, 2.45-5.79) in the placebo group, giving an adjusted rate ratio for isoniazid versus placebo of 0.92 (95% CI, 0.49-1.71). The adjusted rate ratio for tuberculosis for isoniazid versus placebo for tuberculin skin test (TST)-positive subjects was 0.60 (95% CI, 0.23-1.60) and for the TST-negative subjects, 1.23 (95% CI, 0.55-2.76). The overall adjusted mortality rate ratio for isoniazid versus placebo was 1.18 (95% Cl, 0.79-1.75). Stratifying by TST reactivity gave an adjusted mortality rate ratio in those who were TST-positive of 0.33 (95% CI, 0.09-1.23) and for TST-negative subjects, 1.39 (95% CI, 0.90-2.12). Conclusions: Overall there was no statistically significant protective effect of daily isoniazid for 6 months in the prevention of tuberculosis. In the TST-positive subjects, where reactivation is likely to be the more important pathogenetic mechanism, there was some protection and some reduction in mortality, although this was not statistically significant. The small number of individuals in this subgroup made the power to detect a statistically significant difference in this subgroup low. Other influences that may have diluted the efficacy of isoniazid include a high rate of transmission of new infection and rapid progression to disease or insufficient duration of isoniazid in subjects with relatively advanced immunosuppression. The rate of drug resistance observed in subjects who received isoniazid and subsequently developed tuberculosis was low.
引用
收藏
页码:875 / 882
页数:8
相关论文
共 50 条
  • [1] Randomized controlled trial of isoniazid preventive therapy in HIV-infected persons on antiretroviral therapy
    Rangaka, M. X.
    Boulle, A.
    Wilkinson, R. J.
    van Cutsem, G.
    Goemaere, E.
    Goliath, R.
    Titus, R.
    Mathee, S.
    Maartens, G.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 49 - 50
  • [2] Isoniazid Preventive Therapy For Mycobacterium Tuberculosis Infection Among Hiv-1-Infected Persons In Los Angeles County, California, Usa
    Shin, S. S.
    Chang, A. H.
    Ghosh, J.
    Dube, M. P.
    Yang, O. O.
    Kerndt, P. R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [3] Isoniazid preventive therapy for HIV infected children: Impact on incidence of tuberculosis?
    Mitchell, C. D.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 21 : 55 - 55
  • [4] Randomized, placebo-controlled trial of Chinese herb therapy for HIV-1-infected individuals
    Weber, R
    Christen, L
    Loy, M
    Schaller, S
    Christen, S
    Joyce, CRB
    Ledermann, U
    Ledergerber, B
    Cone, R
    Lüthy, R
    Cohen, MR
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 22 (01) : 56 - 64
  • [5] Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting
    Padmapriyadarsini, C.
    Sekar, L.
    Reddy, Devarajulu
    Chitra, Anandha
    Poornagangadevi, N.
    Selvaraj, M.
    Bhavani, P. K.
    Mothi, S. N.
    Nandagopal, K.
    Vennila, S.
    Tamizhselvan, M.
    Maheshmanisha, J.
    Agarwal, Upasna
    Rewari, B. B.
    Swaminathan, Soumya
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2020, 152 (06) : 648 - 655
  • [6] Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease
    Mohammed, A.
    Myer, L.
    Ehrlich, R.
    Wood, R.
    Cilliers, F.
    Maartens, G.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2007, 11 (10) : 1114 - 1120
  • [7] Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort
    Golub, Jonathan E.
    Pronyk, Paul
    Mohapi, Lerato
    Thsabangu, Nkeko
    Moshabela, Mosa
    Struthers, Helen
    Gray, Glenda E.
    McIntyre, James A.
    Chaisson, Richard E.
    Martinson, Neil A.
    AIDS, 2009, 23 (05) : 631 - 636
  • [8] Anti-tuberculosis treatment outcomes in HIV-infected adults exposed to isoniazid preventive therapy in Botswana
    Sibanda, T.
    Tedla, Z.
    Nyirenda, S.
    Agizew, T.
    Marape, M.
    Miranda, A. G.
    Reuter, H.
    Johnson, J. L.
    Samandari, T.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2013, 17 (02) : 178 - 185
  • [9] Screening for active tuberculosis before isoniazid preventive therapy among HIV-infected West African adults
    Moh, R.
    Badje, A.
    N'takpe, J-B.
    Kouame, G. M.
    Gabillard, D.
    Ouassa, T.
    Ouattara, E.
    Le Carrou, J.
    Bohoussou, F.
    Messou, E.
    Eholie, S.
    Anglaret, X.
    Danel, C.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2017, 21 (12) : 1237 - +
  • [10] The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting
    Frigati, L. J.
    Kranzer, K.
    Cotton, M. F.
    Schaaf, H. S.
    Lombard, C. J.
    Zar, H. J.
    THORAX, 2011, 66 (06) : 496 - 501